Tumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast Cancer

Tumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast Cancer

Human epidermal growth factor receptor 2–positive (HER2-positive) breast cancer accounts for 15 to 25% of breast cancer cases. Although therapies based on the use of monoclonal anti-HER2 antibodies present clinical benefit for a subtype of patients with HER2-positive breast cancer, more than 50% of...

Full description

Bibliographic Details
Main Authors: Melani Luque, Marta Sanz-Álvarez, Miriam Morales-Gallego, Juan Madoz-Gúrpide, Sandra Zazo, Carolina Domínguez, Alicia Cazorla, Yann Izarzugaza, Juan Luis Arranz, Ion Cristóbal, Federico Rojo
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Cancers
Subjects:
HER2-positive breast cancer
immunotherapy
tumor-infiltrating lymphocytes
Online Access:https://www.mdpi.com/2072-6694/14/24/6034

Internet

https://www.mdpi.com/2072-6694/14/24/6034

Similar Items